Bimekizumab

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data published in RMD Open.

Ethan Craig, MD, spoke with Healio about treatment options coming up in the pipeline for psoriatic arthritis.

Ethan Craig, MD, spoke with Healio about treatment options currently available in psoriatic arthritis.

The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.

Patients with scalp and palmoplantar psoriasis treated with bimekizumab had a high rate of clearance maintained through 4 years of treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.

Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.

Patients treated with bimekizumab for moderate to severe hidradenitis suppurativa exhibited rapid and clinically meaningful responses that were maintained up to 48 weeks, according to new data published in The Lancet.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the BE BRIGHT study.

Hepatic adverse events with bimekizumab were low and consistent through 2 years of treatment among patients with moderate to severe psoriasis, according to a study.